EGFR and non-small cell lung carcinoma: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have achieved good efficacy and safety in some patients with advanced EGFR mutation-negative NSCLC, but their benefits in patients with previous EGFR mutations are limited (4–6).